December 07, 2018
1 min read
Save

EyeGate posts decreased quarterly loss

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

EyeGate Pharmaceuticals reported a net loss of $3.124 million in the third quarter of 2018 compared with a net loss of $4.140 million in the third quarter of 2017, according to a press release.

Revenues increased from $0.075 million to $0.315 million in the quarter, which the company attributed to milestone payments from Bausch Health Companies.

Research and development costs were down from $3.176 million in 2017’s third quarter to $2.260 million this year, mostly due to decreases in clinical activity for EGP-437 trials.

General and administrative expenses increased from $1.039 million to $1.233 million for the quarter.

The company had cash and cash equivalents totaling $9.9 million as of Sept. 30.